8-K: Lisata Therapeutics Extends Cash Runway into Q4 2026, Advances Certepetide Towards Global Phase 3 in Pancreatic Cancer

Lisata Therapeutics announced an extension of its cash runway into the fourth quarter of 2026, alongside significant clinical progress for its lead asset, Certepetide, including an agreed-upon Phase 3 study design with the FDA for metastatic pancreatic ductal adenocarcinoma.

Summary

• Lisata Therapeutics, a clinical-stage company, is developing Certepetide, a novel solid tumor targeting and penetration technology with tumor microenvironment (TME) modifying properties.
• The company has extended its projected cash runway from the third quarter of 2026 to the fourth quarter of 2026, with approximately $25.8 million in cash, cash equivalents, and marketable securities as of March 31, 2025, and no debt.
• Certepetide is designed to enhance the treatment benefits of existing and emerging therapies for solid tumors by converting tumor stroma into a conduit for anti-cancer drugs, selectively reducing immunosuppressive T cells, and inhibiting metastasis.
• The company has a strong intellectual property portfolio for Certepetide, with composition of matter patents extending beyond 2040, potentially to 2046 with extensions.
• Existing partnerships include Qilu Pharmaceutical (exclusive rights in Greater China), Kuva Labs (diagnostic tumor imaging), Catalent, Inc. (preclinical evaluation with SMARTag platform), and GATC Health Corp. (AI-derived assets).
• In metastatic pancreatic ductal adenocarcinoma (mPDAC), Certepetide has shown improved overall survival in two independent Phase 1b/2a trials (CEND1-001 and CEND1-201) when combined with gemcitabine/nab-paclitaxel, akin to the recently FDA-approved NALIRIFOX triplet therapy.
• Preliminary data from the ASCEND Phase 2b Cohort A in mPDAC showed no statistically significant improvement in progression-free survival (PFS) but a numerical favor in median overall survival (mOS) for the Certepetide + SoC arm (12.68 months) compared to SoC alone (9.72 months), with 4 complete responses in the Certepetide group.
• Preliminary efficacy data from the iLSTA Phase 1b/2a trial in locally advanced non-resectable PDAC showed a 69% Objective Response Rate (ORR) and 100% Disease Control Rate (DCR) in Cohort 3 (Certepetide + durvalumab + gemcitabine/nab-paclitaxel) as of May 2025.
• Certepetide has demonstrated a sustained complete response for over 31 months in a patient with metastatic gastroesophageal adenocarcinoma (mGEAC) when added to standard chemotherapy, radiotherapy, and immunotherapy.
• The company has received FDA Fast Track Designation for pancreatic cancer, and Orphan Drug Designations for pancreatic cancer, malignant glioma, osteosarcoma, and cholangiocarcinoma, along with Rare Pediatric Disease Designation for osteosarcoma.
• Lisata has completed an End-of-Phase 2 FDA meeting, reaching agreement on the design for a global Phase 3 open-label, randomized clinical trial for Certepetide in combination with gemcitabine and nab-paclitaxel in first-line mPDAC, targeting 657 patients with overall survival as the primary endpoint.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the extended cash runway, clear regulatory path to Phase 3 for a lead asset in a high-need indication, and multiple positive clinical signals across various cancer types. The strong IP and existing partnerships further bolster confidence, despite one Phase 2b cohort not meeting its primary endpoint for statistical significance in PFS, as OS data showed a favorable trend.

Positives

• Extended cash runway into Q4 2026, providing longer operational stability without immediate need for additional financing.
• Agreement with FDA on Phase 3 study design for Certepetide in mPDAC, indicating a clear regulatory path forward.
• Certepetide demonstrated improved median overall survival in two independent Phase 1b/2a trials for mPDAC, showing consistency and potential for significant clinical benefit.
• Preliminary ASCEND Phase 2b Cohort A data showed a numerical favor in median overall survival (12.68 months vs. 9.72 months) and 4 complete responses in the Certepetide arm, suggesting a positive trend.
• High Objective Response Rate (69%) and Disease Control Rate (100%) observed in preliminary iLSTA Phase 1b/2a data for locally advanced PDAC, indicating strong early efficacy signals in combination with immunotherapy and chemotherapy.
• Demonstrated sustained complete response in a metastatic gastroesophageal adenocarcinoma patient, highlighting broad applicability and potentiation of existing therapies.
• Strong intellectual property protection for Certepetide, with composition of matter patents extending to 2041 and potentially 2046.
• Multiple strategic partnerships (Qilu, Kuva Labs, Catalent, GATC Health) validate the platform technology and provide potential for future milestones and royalties.
• Possession of multiple regulatory designations including FDA Fast Track, Orphan Drug, and Rare Pediatric Disease Designation, which offer significant development and commercial benefits, including potential Priority Review Vouchers.

Negatives

• The ASCEND Phase 2b Cohort A did not show a statistically significant improvement in progression-free survival, which was the primary endpoint for this cohort.
• Reliance on future data, specifically the final, definitive data from ASCEND Cohort B expected by mid-2025, to further support the benefit of Certepetide.

Risks

• The safety and efficacy of Lisata's product candidates are subject to clinical trial outcomes and regulatory authority decisions.
• Regulatory delays in clinical programs could impact timelines and costs.
• Lisata's ability to finance its operations and successfully initiate and complete clinical trials depends on available capital.
• The likelihood and timing of receiving future milestone and licensing fees from partnerships are uncertain.
• The future success of Lisata's scientific studies and its ability to successfully develop and commercialize drug candidates are not guaranteed.
• Predicting the time and cost of development for product candidates is difficult.
• Rapid technological change in Lisata's markets could impact the competitive landscape.
• The ability of Lisata to protect its intellectual property rights is crucial for its long-term success.
• Legislative, regulatory, political, and economic developments could adversely affect the company's operations and prospects.

Future Outlook

Lisata Therapeutics is poised for global Phase 3 initiation for Certepetide in first-line metastatic pancreatic ductal adenocarcinoma, following agreement with the FDA on the study design. The company anticipates final data from the ASCEND Phase 2b Cohort B by mid-2025 and plans for a second EMA scientific advice meeting in Autumn 2025. Preclinical studies with Valo Therapeutics and Catalent are targeting data in the second half of 2025, and first-in-human dosing for the GATC-1021 asset for Opioid Use Disorder is targeted for the first half of 2026. The company continues to pursue rapid global registration in mPDAC and demonstrate Certepetide's effectiveness across various solid tumors and treatment regimens.

Management Comments

• David J. Mazzo, PhD, President & Chief Executive Officer, signed the 8-K report on behalf of Lisata Therapeutics, Inc.
• The corporate presentation highlights Dr. Mazzo's over 40 years of experience as a global pharmaceutical executive, noted for strategic prowess and vast experience in developing and launching new products.

Industry Context

The announcement by Lisata Therapeutics is set against a backdrop of a vital and growing global need for improved solid tumor treatments, with cancer incidence projected to rise significantly (from 20 million new cases in 2022 to 35 million by 2050). Solid tumors account for over 90% of all diagnosed cancers, and pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most common cause of cancer mortality by 2030, with current immunotherapies often ineffective. Lisata's Certepetide, by addressing challenging tumor morphology and the immunosuppressive tumor microenvironment, positions itself as a potentially transformative adjuvant that can enhance the efficacy of existing and emerging anti-cancer therapies, offering a solution to the suboptimal outcomes of current treatments.

Comparison to Industry Standards

• In metastatic pancreatic ductal adenocarcinoma (mPDAC), Certepetide combined with standard of care (SoC) gemcitabine/nab-paclitaxel demonstrated median overall survival (mOS) of 13.2 months (CEND1-201 China) and 11.1 months (CEND1-001 Australia), which compares favorably to the 8.5 months mOS established by the Von Hoff 2013 Phase 3 study for SoC alone, aligning with the efficacy seen in the recently FDA-approved NALIRIFOX triplet therapy.
• The ASCEND Phase 2b Cohort A showed a numerical mOS advantage for Certepetide + SoC (12.68 months) over SoC alone (9.72 months), with the separation occurring at 7 months, similar to observations in the NAPOLI-3 study.
• In locally advanced non-resectable PDAC, the iLSTA Phase 1b/2a trial's preliminary data showed a 69% Objective Response Rate and 100% Disease Control Rate in Cohort 3 (Certepetide + durvalumab + gemcitabine/nab-paclitaxel), indicating a strong response in a population often non-responsive to checkpoint inhibition.
• The sustained complete response in a metastatic gastroesophageal adenocarcinoma patient treated with Certepetide alongside FOLFIRINOX, radiotherapy, and pembrolizumab highlights its potential to significantly improve outcomes in difficult-to-treat cancers, beyond standard expectations for these regimens alone.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to extended cash runway, positive clinical trial results, and a clear path to Phase 3, which de-risks the investment.
• Patients: Potential for improved treatment outcomes in various solid tumors, particularly metastatic pancreatic cancer, through enhanced drug delivery and TME modification.
• Employees: Enhanced job security and stability due to the extended cash runway and continued progress in clinical development.
• Partners: Continued and potentially expanded collaboration opportunities as Certepetide advances through clinical stages and demonstrates broader applicability.
• Creditors: No immediate impact as the company reports no debt.

Next Steps

• Initiate a global Phase 3 open-label, randomized clinical trial evaluating Certepetide in combination with standard of care (gemcitabine and nab-paclitaxel) vs. standard of care alone in patients with first-line metastatic pancreatic ductal adenocarcinoma.
• Receive final, definitive data from the ASCEND Phase 2b Cohort B by mid-2025.
• Conduct a second EMA scientific advice meeting in Autumn 2025.
• Target data release for preclinical studies with Valo Therapeutics and Catalent in 2H2025.
• Target first-in-human dosing for the GATC-1021 asset for Opioid Use Disorder in 1H2026.
• Continue clinical development of Certepetide in other solid tumors including cholangiocarcinoma, pancreatic, colon, appendiceal cancers, and glioblastoma multiforme.

Key Dates

Recommendation

Keywords

Lisata Therapeutics, Certepetide, LSTA, Pancreatic Cancer, Solid Tumors, Oncology, Clinical-Stage, Biotechnology, Drug Development, Targeted Therapy, Tumor Microenvironment, SEC Filing, 8-K, Metastatic Pancreatic Ductal Adenocarcinoma, Cholangiocarcinoma, Glioblastoma, iRGD, Clinical Trials, FDA Fast Track, Orphan Drug Designation, Corporate Presentation